Mahamaya Lifesciences IPO Lists at ₹116 on BSE SME Against the Issue Price of ₹114

New Delhi, November 18: Mahamaya Lifesciences IPO made its debut on the BSE SME platform today, listing at ₹116 per share, slightly above the IPO’s upper issue price of ₹114. The stock surged soon after listing, reaching an early high of ₹121.80, a 6.84% gain from the opening price.

Shares opened at ₹116, giving the SME IPO a 1.75% premium over its issue price. During the initial phase of trading, the stock touched its 5% upper circuit of ₹121.80, reflecting strong buying interest even as the broader market trended lower.

By midday, Mahamaya Lifesciences was trading at ₹116.05, maintaining its gains while benchmark indices remained in the red. The movement on debut day indicated that, although the start was modest, investors were keen to engage with the stock.

Mahamaya Lifesciences is an Indian agrochemical and biological solutions company. It is engaged in the manufacturing, formulation, and marketing of a wide range of crop protection products, including insecticides, fungicides, and herbicides, as well as bio-stimulants. The company supplies bulk formulations to both domestic agrochemical companies and multinational corporations.

Mahamaya Lifesciences IPO Key Details

The ₹70.44 crore Mahamaya Lifesciences IPO was a combination of fresh issue of 0.56 crore shares aggregating to ₹64.28 crores and offer for sale of 0.05 crore shares aggregating to ₹6.16 crores. Mahamaya Lifesciences’ IPO price band was finalised at ₹114 per share, at the upper price of the band. The lot size was 1,200 shares per application. The minimum investment amount required by a retail investor was ₹2,73,600 (2,400 shares) at the upper price band. Oneview Corporate Advisors Pvt. Ltd. was the book running lead manager, and Kfin Technologies Ltd. was the registrar of the issue. The Market Maker of the company was Mansi Share & Stock Broking Pvt.Ltd.

Mahamaya Lifesciences IPO Subscription Status

Mahamaya Lifesciences IPO subscribed 1.63 times. The public issue subscribed 1.02 times in the individual investors category, 1.19 times in QIB (Ex Anchor), and 3.63 times in the NII category

Mahamaya Lifesciences IPO Anchor Allocation Details

Ahead of the IPO, Mahamaya Lifesciences raised ₹19.99 crore from anchor investors by allocating 17,52,000 shares at ₹114 per share. Key investors included Abundantia Capital, Ascend Global Opportunities Fund, Ebisu Global Opportunities Fund, Vikasa India EIF Incube Global Opportunities, Aarthi AIF Growth Fund, Navbharat Investment Opportunities Fund, and NAV Capital Emerging Star Fund.

Investor Takeaway for Mahamaya Lifesciences

Mahamaya Lifesciences made its debut on the BSE SME platform with a listing price of ₹116 per share, just 1.75% above its IPO issue price of ₹114. Despite strong anchor allocation and investor interest during the IPO, the listing gains were modest. Investors will now watch how the stock performs in the coming days to assess potential returns on their investment.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations